文献速递免疫规划卫生政策与健康促进

美国现行许可乙型肝炎表面抗原疫苗的安全性:疫苗不良事件报告系统(VAERS)2005-2015年

Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
PubMed 文献 · Vaccine · 2017-12-11

研究检索2005年1月至2015年12月VAERS中单抗原乙型肝炎疫苗及含乙型肝炎疫苗成分的疫苗报告,共20,231份,其中51%为2岁以下儿童。描述性分析与经验贝叶斯数据挖掘未发现新的或意外的安全信号;单抗原乙型肝炎疫苗报告中最常见不良事件为头晕和恶心(各8.4%),含乙型肝炎疫苗成分疫苗报告中最常见为发热(23%)和注射部位红斑(11%)。结论认为现行美国许可乙型肝炎疫苗未揭示新的或意外的安全问题,但发现接种差错,提示需对提供者进行培训教育。

要点

  • VAERS在2005-2015年共收到20,231份乙型肝炎或含乙型肝炎疫苗成分疫苗报告,51%为2岁以下儿童。
  • 单抗原乙型肝炎疫苗报告中最常见不良事件为头晕和恶心(各8.4%);含乙型肝炎疫苗成分疫苗报告中最常见为发热(23%)和注射部位红斑(11%)。
  • 单抗原乙型肝炎疫苗报告中最常见接种差错为不正确产品储存;审查未发现新的或意外安全信号。

核心结论

  • 审查美国现行许可的单独接种或与其他疫苗联合接种的乙型肝炎疫苗,未发现新的或意外的安全问题。
  • 发现接种差错,提示需要对提供者进行乙型肝炎疫苗适应症和推荐相关的培训与教育。

研究设计与样本

  • 检索疫苗不良事件报告系统(VAERS)2005年1月至2015年12月单抗原乙型肝炎疫苗及含乙型肝炎疫苗成分疫苗(单独或与其他疫苗同时接种)的不良事件报告。
  • 进行描述性分析,并采用经验贝叶斯数据挖掘评估不成比例报告。
  • 审查严重报告,包括特别关注报告。

主要发现

  • VAERS共收到20,231份乙型肝炎或含乙型肝炎疫苗成分疫苗报告:10,291份(51%)为2岁以下者,2,588份(13%)为2-18岁者,5,867份(29%)为18岁以上者,1,485份(7.3%)年龄缺失。
  • 单抗原乙型肝炎疫苗报告中最常见不良事件为头晕和恶心(各8.4%);含乙型肝炎疫苗成分疫苗报告中最常见为发热(23%)和注射部位红斑(11%)。
  • 单抗原乙型肝炎疫苗报告共4,444份(22%),其中303份(6.8%)为严重报告,包括45例死亡;最常报告的死亡原因为婴儿猝死综合征(197例)。
  • 单抗原乙型肝炎疫苗后最常见非死亡严重报告:1月龄以下婴儿为神经系统疾病(15例);1-23月龄儿童为感染和侵染(8例);2-18岁者为血液和淋巴系统疾病;18岁以上者为全身性疾病和给药部位状况。
  • 单抗原乙型肝炎疫苗后最常见接种差错为不正确产品储存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Currently four recombinant hepatitis B (HepB) vaccines are in use in the United States. HepB vaccines are recommended for infants, children and adults. We assessed adverse events (AEs) following HepB vaccines reported to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system. METHODS: We searched VAERS for reports of AEs following single antigen HepB vaccine and HepB-containing vaccines (either given alone or with other vaccines), from January 2005 - December 2015. We conducted descriptive analyses and performed empirical Bayesian data mining to assess disproportionate reporting. We reviewed serious reports including reports of special interest. RESULTS: VAERS received 20,231 reports following HepB or HepB-containing vaccines: 10,291 (51%) in persons <2 years of age; 2588 (13%) in persons 2-18 years and 5867 (29%) in persons >18 years; for 1485 (7.3%) age was missing. Dizziness and nausea (8.4% each) were the most frequently reported AEs following a single antigen HepB vaccine: fever (23%) and injection site erythema (11%) were most frequent following Hep-containing vaccines. Of the 4444 (22%) reports after single antigen HepB vaccine, 303 (6.8%) were serious, including 45 deaths. Most commonly reported cause of death was Sudden Infant Death Syndrome (197). Most common non-death serious reports following single antigen HepB vaccines among infants aged <1 month, were nervous system disorders (15) among children aged 1-23 months; infections and infestation (8) among persons age 2-18 years blood and lymphatic systemic disorders; and general disorders and administration site conditions among persons age >18 years. Most common vaccination error following single antigen HepB was incorrect product storage. CONCLUSIONS: Review current U.S.-licensed HepB vaccines administered alone or in combination with other vaccines did not reveal new or unexpected safety concerns. Vaccination errors were identified which indicate the need for training and education of providers on HepB vaccine indications and recommendations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haber P, Moro PL, Ng C, et al. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015. Vaccine. 2017. PMID: 29241647. doi:10.1016/j.vaccine.2017.11.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。